Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on DAR. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN112876355B reveals a novel Co-N-C catalyzed route for converting secondary alcohols to esters via C-C bond cleavage, offering superior yields and greener processing for pharmaceutical supply chains.
Patent CN110627768B reveals a novel synthesis for Moxifloxacin degradation impurity J. Achieve high-purity reference standards with scalable, cost-effective manufacturing processes.
Patent CN117757876A reveals double-enzyme catalysis for 2'-F-dAR. Offers simplified process, cost reduction in pharmaceutical intermediates manufacturing, and high purity.
Novel patent CN109053652A offers high-purity Amiodarone intermediate synthesis with improved yield and scalability for global supply chains.
Patent CN117659033B analysis reveals high-purity darunavir intermediate synthesis via photocatalysis offering substantial supply chain and cost advantages for manufacturers.
Patent CN108358793B details a green one-pot synthesis of secondary amines from alkynes, offering significant cost reduction in API manufacturing without metal catalysts.
Novel synthesis of deuterated quinoxaline-2-carboxylic acid via SeO2 oxidation. High purity >98% for veterinary drug residue analysis.
Patent CN111362999B details a novel oxidation method for Epristeride impurity. This report analyzes cost reduction in API manufacturing and high-purity reference standard production.
Patent CN112745273A reveals a high-yield synthesis for Nifuratel impurity standards, offering reliable supply chain solutions and cost-effective manufacturing for pharmaceutical quality control.
Advanced preparation method for Pioglitazone Related Substance D ensuring high purity. Optimized synthetic route for pharmaceutical quality control and reference standards.
Patent CN101085990A reveals chemo-enzymatic route for high-purity chiral alcohols. Enables cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN110372641B reveals a novel enzymatic route for hexahydrofurofuranol derivatives, offering high optical purity and cost-effective manufacturing for API supply chains.
Analysis of patent CN101085990B reveals a chemo-enzymatic route for high-purity chiral alcohols. This method offers significant supply chain stability and cost reduction advantages for pharmaceutical intermediate manufacturing.
Patent CN106866763A offers high purity Vidarabine Monophosphate synthesis. Reduces impurities and enhances supply chain reliability for pharmaceutical manufacturers globally.
Patent CN103562196A reveals a novel reductive amination route for Dronedarone intermediates, offering high purity and scalable API manufacturing solutions.
Patent CN118530145A details a safer route for Darunavir intermediates. High purity above 98 percent ensures supply chain stability and significant cost reduction in API intermediate manufacturing processes.
Novel route for Amiodarone Impurity C offers high purity and cost efficiency. Enhances supply chain stability for API manufacturers seeking qualified reference substances.
Patent CN102336710B reveals efficient synthesis route. Offers cost reduction and supply chain reliability for high-purity pharmaceutical intermediates manufacturing globally.
Patent CN111170886B details a novel mild oxidation and demethylation route for dezocine impurities, ensuring high purity and scalable pharmaceutical intermediate manufacturing.
Advanced preparation method for Zoledronic Acid Impurity B via optimized phosphorylation. High purity >98% reference standards for global pharmaceutical quality control.